AAAAAA
Results:
1-10
|
Results: 10
Authors:
Barlogie, B
Zangari, M
Spencer, T
Fassas, A
Anaissie, E
Badros, A
Cromer, J
Tricot, G
Citation: B. Barlogie et al., Thalidomide in the management of multiple myeloma, SEM HEMATOL, 38(3), 2001, pp. 250-259
Authors:
Badros, A
Barlogie, B
Siegel, E
Roberts, J
Langmaid, C
Zangari, M
Desikan, R
Shaver, MJ
Fassas, A
McConnell, S
Muwalla, F
Barri, Y
Anaissie, E
Munshi, N
Tricot, G
Citation: A. Badros et al., Results of autologous stem cell transplant in multiple myeloma patients with renal failure, BR J HAEM, 114(4), 2001, pp. 822-829
Authors:
Badros, A
Barlogie, B
Siegel, E
Morris, C
Desikan, R
Zangari, M
Fassas, A
Anaissie, E
Munshi, N
Tricot, G
Citation: A. Badros et al., Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years, BR J HAEM, 114(3), 2001, pp. 600-607
Authors:
Desikan, KR
Tricot, G
Munshi, NC
Anaissie, E
Spoon, D
Fassas, A
Toor, A
Zangari, M
Badros, A
Morris, C
Vesole, DH
Siegel, D
Jagannath, S
Barlogie, B
Citation: Kr. Desikan et al., Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone, BR J HAEM, 112(1), 2001, pp. 242-247
Authors:
Zangari, M
Anaissie, E
Barlogie, B
Badros, A
Desikan, R
Gopal, AV
Morris, C
Toor, A
Siegel, E
Fink, L
Tricot, G
Citation: M. Zangari et al., Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy, BLOOD, 98(5), 2001, pp. 1614-1615
Authors:
Badros, A
Barlogie, B
Morris, C
Desikan, R
Martin, SR
Munshi, N
Zangari, M
Mehta, J
Toor, A
CottlerFox, M
Fassas, A
Aniassie, E
Schichman, S
Tricot, G
Citation: A. Badros et al., High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions (vol 97, pg 2574, 2001), BLOOD, 98(2), 2001, pp. 271-271
Authors:
Barlogie, B
Desikan, R
Eddlemon, P
Spencer, T
Zeldis, J
Munshi, N
Badros, A
Zangari, M
Anaissie, E
Epstein, J
Shaughnessy, J
Ayers, D
Spoon, D
Tricot, G
Citation: B. Barlogie et al., Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 studyof 169 patients, BLOOD, 98(2), 2001, pp. 492-494
Authors:
Badros, A
Barlogie, B
Morris, C
Desikan, R
Martin, SR
Munshi, N
Zangari, M
Toor, A
Cottler-Fox, M
Fassas, A
Aniassie, E
Schichman, S
Tricot, G
Citation: A. Badros et al., High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions, BLOOD, 97(9), 2001, pp. 2574-2579
Authors:
Desikan, R
Barlogie, D
Sawyer, J
Ayers, D
Tricot, G
Badros, A
Zangari, M
Munshi, NC
Anaissle, E
Spoon, D
Siegel, D
Jagannath, S
Vesole, D
Epstein, J
Shaughnessy, J
Fassas, A
Lim, S
Roberson, P
Crowley, J
Citation: R. Desikan et al., Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities, BLOOD, 95(12), 2000, pp. 4008-4010
Authors:
Zangari, M
Henzlova, MJ
Ahmad, S
Scigliano, E
Isola, L
Platnik, J
Croft, LB
Sandler, D
Diamond, JA
Machac, J
Fruchtman, SM
Citation: M. Zangari et al., Predictive value of left ventricular ejection fraction in stem cell transplantation, BONE MAR TR, 23(9), 1999, pp. 917-920
Risultati:
1-10
|